m6A Regulator and Potential Drug Response
General Information of the m6A Regulator (ID: REG00024)
| Regulator Name | YTH domain-containing family protein 1 (YTHDF1) | ||||
|---|---|---|---|---|---|
| Synonyms |
DF1; Dermatomyositis associated with cancer putative autoantigen 1; DACA-1; C20orf21
Click to Show/Hide
|
||||
| Gene Name | YTHDF1 | ||||
| Regulator Type | WRITER ERASER READER | ||||
| Regulator Link | Click to View Full Information of This Regulator | ||||
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Aldo-keto reductase 1C1 (AKR1C1)
Dihydrotestosterone [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aldo-keto reductase 1C1 (AKR1C1) is a therapeutic target for Dihydrotestosterone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Dihydrotestosterone through regulating the expression of Aldo-keto reductase 1C1 (AKR1C1). | [1], [2] | ||
Fenofibric acid [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aldo-keto reductase 1C1 (AKR1C1) is a therapeutic target for Fenofibric acid. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Fenofibric acid through regulating the expression of Aldo-keto reductase 1C1 (AKR1C1). | [1], [3] | ||
Nabumetone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aldo-keto reductase 1C1 (AKR1C1) is a therapeutic target for Nabumetone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Nabumetone through regulating the expression of Aldo-keto reductase 1C1 (AKR1C1). | [1], [4] | ||
Progesterone [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aldo-keto reductase 1C1 (AKR1C1) is a therapeutic target for Progesterone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Progesterone through regulating the expression of Aldo-keto reductase 1C1 (AKR1C1). | [1], [2] | ||
AK-602 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aldo-keto reductase 1C1 (AKR1C1) is a therapeutic target for AK-602. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AK-602 through regulating the expression of Aldo-keto reductase 1C1 (AKR1C1). | [1], [5] | ||
BRN-3548355 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Aldo-keto reductase 1C1 (AKR1C1) is a therapeutic target for BRN-3548355. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BRN-3548355 through regulating the expression of Aldo-keto reductase 1C1 (AKR1C1). | [1], [6] | ||
Apoptosis regulator Bcl-2 (BCL-2)
MCI-186 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for MCI-186. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MCI-186 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [8] | ||
Venetoclax [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Venetoclax. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Venetoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [9] | ||
ABT-263 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-263. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABT-263 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [10] | ||
Oblimersen [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Oblimersen. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Oblimersen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [11] | ||
RG7601 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for RG7601. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RG7601 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [12] | ||
Thymoquinone [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [13] | ||
APG-1252 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-1252. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of APG-1252 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [14] | ||
APG-2575 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for APG-2575. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of APG-2575 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [15] | ||
AZD0466 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AZD0466. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AZD0466 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [16] | ||
Beclanorsen [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Beclanorsen. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Beclanorsen through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [17] | ||
Gossypol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Gossypol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Gossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [18] | ||
Obatoclax [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Obatoclax. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Obatoclax through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [19] | ||
PNT-2258 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for PNT-2258. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PNT-2258 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [20] | ||
AI-850 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for AI-850. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AI-850 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [21] | ||
BCL201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BCL201. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BCL201 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [22] | ||
BGB-11417 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BGB-11417. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BGB-11417 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [23] | ||
BP1002 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP1002. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BP1002 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [24] | ||
LP-108 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for LP-108. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LP-108 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [25] | ||
Pc4 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Pc4. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Pc4 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [26] | ||
VOB560 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for VOB560. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of VOB560 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [27] | ||
2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [28] | ||
4,5-dibenzylbenzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 4,5-dibenzylbenzene-1,2-diol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4,5-dibenzylbenzene-1,2-diol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [29] | ||
5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [30] | ||
Apogossypol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Apogossypol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Apogossypol through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [31] | ||
BP-100-1.02 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for BP-100-1.02. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BP-100-1.02 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [32] | ||
modified HA14-1 compounds (cancer) [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for modified HA14-1 compounds (cancer). The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of modified HA14-1 compounds (cancer) through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [30] | ||
N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [30] | ||
QEDIIRNIARHLAQVGDSMDR [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for QEDIIRNIARHLAQVGDSMDR. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of QEDIIRNIARHLAQVGDSMDR through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [30] | ||
TW-37 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for TW-37. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TW-37 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [33] | ||
WL-276 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for WL-276. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of WL-276 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [34] | ||
ABT-737 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for ABT-737. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABT-737 through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [7], [35] | ||
Beta-catenin (CTNNB1)
Recombinant human endostatin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Beta-catenin (CTNNB1) is a therapeutic target for Recombinant human endostatin. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Recombinant human endostatin through regulating the expression of Beta-catenin (CTNNB1). | [36], [37] | ||
C 82 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Beta-catenin (CTNNB1) is a therapeutic target for C 82. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of C 82 through regulating the expression of Beta-catenin (CTNNB1). | [36], [38] | ||
CEQ-508 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Beta-catenin (CTNNB1) is a therapeutic target for CEQ-508. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CEQ-508 through regulating the expression of Beta-catenin (CTNNB1). | [36], [39] | ||
Caterpiller protein 1.1 (NLRP3)
Dapansutrile [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caterpiller protein 1.1 (NLRP3) is a therapeutic target for Dapansutrile. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Dapansutrile through regulating the expression of Caterpiller protein 1.1 (NLRP3). | [40], [41] | ||
BMS-986299 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caterpiller protein 1.1 (NLRP3) is a therapeutic target for BMS-986299. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BMS-986299 through regulating the expression of Caterpiller protein 1.1 (NLRP3). | [40], [42] | ||
MCC950 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Caterpiller protein 1.1 (NLRP3) is a therapeutic target for MCC950. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MCC950 through regulating the expression of Caterpiller protein 1.1 (NLRP3). | [40], [43] | ||
Cellular tumor antigen p53 (TP53)
Contusugene ladenovec [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Contusugene ladenovec. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Contusugene ladenovec through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [45] | ||
QPI-1002 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for QPI-1002. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of QPI-1002 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [46] | ||
Thymoquinone [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [47] | ||
Ad-p53 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Ad-p53. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Ad-p53 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [48] | ||
ALT-801 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for ALT-801. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ALT-801 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [49] | ||
APG-115 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for APG-115. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of APG-115 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [50] | ||
APR-246 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for APR-246. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of APR-246 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [51] | ||
Cenersen [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Cenersen. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Cenersen through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [52] | ||
INGN-225 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for INGN-225. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of INGN-225 through regulating the expression of Cellular tumor antigen p53 (TP53). | [21], [44] | ||
ISA-P53-01 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for ISA-P53-01. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ISA-P53-01 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [53] | ||
Kevetrin [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Kevetrin. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Kevetrin through regulating the expression of Cellular tumor antigen p53 (TP53). | [19], [44] | ||
OPI-1002 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for OPI-1002. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of OPI-1002 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [54] | ||
SGT-53 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for SGT-53. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SGT-53 through regulating the expression of Cellular tumor antigen p53 (TP53). | [21], [44] | ||
CGM097 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for CGM097. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CGM097 through regulating the expression of Cellular tumor antigen p53 (TP53). | [21], [44] | ||
COTI-2 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for COTI-2. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of COTI-2 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [55] | ||
Dendritic cell vaccine [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Dendritic cell vaccine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Dendritic cell vaccine through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [56] | ||
HDM201 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for HDM201. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HDM201 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [57] | ||
ONYX-015 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for ONYX-015. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ONYX-015 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [58] | ||
SAR-405838 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for SAR-405838. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SAR-405838 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [45] | ||
1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [59] | ||
AHL [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for AHL. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AHL through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [60] | ||
NU-8231 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for NU-8231. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NU-8231 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [61] | ||
NUTLIN-3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for NUTLIN-3. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NUTLIN-3 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [62] | ||
INGN-234 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for INGN-234. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of INGN-234 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [63] | ||
Pifithrin-alpha [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Pifithrin-alpha. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Pifithrin-alpha through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [64] | ||
TAR-1 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for TAR-1. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TAR-1 through regulating the expression of Cellular tumor antigen p53 (TP53). | [44], [65] | ||
CREB-binding protein (CREBBP)
C 82 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for C 82. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of C 82 through regulating the expression of CREB-binding protein (CREBBP). | [66], [67] | ||
CCS1477 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for CCS1477. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CCS1477 through regulating the expression of CREB-binding protein (CREBBP). | [66], [68] | ||
PRI-724 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for PRI-724. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PRI-724 through regulating the expression of CREB-binding protein (CREBBP). | [39], [66] | ||
FT-7051 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for FT-7051. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of FT-7051 through regulating the expression of CREB-binding protein (CREBBP). | [66], [69] | ||
I-CBP112 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for I-CBP112. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of I-CBP112 through regulating the expression of CREB-binding protein (CREBBP). | [66], [70] | ||
ischemin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for ischemin. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ischemin through regulating the expression of CREB-binding protein (CREBBP). | [66], [71] | ||
SGC-CBP30 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | CREB-binding protein (CREBBP) is a therapeutic target for SGC-CBP30. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SGC-CBP30 through regulating the expression of CREB-binding protein (CREBBP). | [66], [72] | ||
Cyclin-dependent kinase 2 (CDK2)
PHA848125 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PHA848125. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PHA848125 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [73] | ||
Ro 31-7453 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Ro 31-7453. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Ro 31-7453 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [74] | ||
Roscovitine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Roscovitine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Roscovitine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [75] | ||
TG02 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for TG02. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TG02 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [76] | ||
AG-024322 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for AG-024322. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AG-024322 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [77] | ||
AT7519 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for AT7519. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AT7519 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [78] | ||
AZD-5438 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for AZD-5438. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AZD-5438 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [79] | ||
CYC065 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for CYC065. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CYC065 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [80] | ||
FN-1501 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for FN-1501. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of FN-1501 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [81] | ||
PF-07104091 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PF-07104091. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PF-07104091 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [82] | ||
PHA-793887 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PHA-793887. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PHA-793887 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [83] | ||
RGB-286638 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for RGB-286638. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RGB-286638 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [76] | ||
SNS-032 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for SNS-032. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SNS-032 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [21] | ||
INOC-005 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for INOC-005. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of INOC-005 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [73] | ||
L-751250 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for L-751250. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of L-751250 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [76] | ||
1-Amino-6-Cyclohex-3-Enylmethyloxypurine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 1-Amino-6-Cyclohex-3-Enylmethyloxypurine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 1-Amino-6-Cyclohex-3-Enylmethyloxypurine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [41] | ||
10Z-Hymenialdisine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 10Z-Hymenialdisine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 10Z-Hymenialdisine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [73] | ||
2-Amino-6-Chloropyrazine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 2-Amino-6-Chloropyrazine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-Amino-6-Chloropyrazine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [41] | ||
2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [51] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [84] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [85] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [86] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [84] | ||
4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [41] | ||
4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [51] | ||
4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [41] | ||
5-hydroxynaphthalene-1-sulfonamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 5-hydroxynaphthalene-1-sulfonamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 5-hydroxynaphthalene-1-sulfonamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [51] | ||
6-(3-Amino-benzyloxy)-9H-purin-2-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-(3-Amino-benzyloxy)-9H-purin-2-ylamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6-(3-Amino-benzyloxy)-9H-purin-2-ylamine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [87] | ||
6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [88] | ||
6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [88] | ||
6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [73] | ||
6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [88] | ||
6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [51] | ||
6-O-Cyclohexylmethyl Guanine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 6-O-Cyclohexylmethyl Guanine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6-O-Cyclohexylmethyl Guanine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [41] | ||
9-Nitropaullone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for 9-Nitropaullone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 9-Nitropaullone through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [73] | ||
aloisine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for aloisine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of aloisine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [89] | ||
aloisine A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for aloisine A. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of aloisine A through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [90] | ||
aminopurvalanol A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for aminopurvalanol A. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of aminopurvalanol A through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [91] | ||
Benzyl-(9-isopropyl-9H-purin-6-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Benzyl-(9-isopropyl-9H-purin-6-yl)-amine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Benzyl-(9-isopropyl-9H-purin-6-yl)-amine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [41] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BMS 536924. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BMS 536924 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [92] | ||
BMS-265246 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BMS-265246. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BMS-265246 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [93] | ||
BOHEMINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BOHEMINE. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BOHEMINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [51] | ||
BX-795 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BX-795. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BX-795 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [93] | ||
BX-912 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BX-912. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BX-912 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [94] | ||
Cdk4 inhibitor III [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Cdk4 inhibitor III. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Cdk4 inhibitor III through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [95] | ||
CVT-313 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for CVT-313. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CVT-313 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [96] | ||
Double Oxidized Cysteine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Double Oxidized Cysteine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Double Oxidized Cysteine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [95] | ||
GW-8510 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for GW-8510. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of GW-8510 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [92] | ||
Indirubin-3'-monoxime [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Indirubin-3'-monoxime. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Indirubin-3'-monoxime through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [73] | ||
Indirubin-5-sulfonate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Indirubin-5-sulfonate. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Indirubin-5-sulfonate through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [73] | ||
JNJ 7706621 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for JNJ 7706621. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of JNJ 7706621 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [84] | ||
K00024 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for K00024. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of K00024 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [97] | ||
Lysine Nz-Carboxylic Acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Lysine Nz-Carboxylic Acid. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Lysine Nz-Carboxylic Acid through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [51] | ||
MERIOLIN 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 1. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MERIOLIN 1 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [84] | ||
MERIOLIN 2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 2. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MERIOLIN 2 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [98] | ||
MERIOLIN 3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 3. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MERIOLIN 3 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [98] | ||
MERIOLIN 4 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 4. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MERIOLIN 4 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [98] | ||
MERIOLIN 5 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 5. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MERIOLIN 5 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [98] | ||
MERIOLIN 6 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 6. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MERIOLIN 6 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [98] | ||
MERIOLIN 8 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for MERIOLIN 8. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MERIOLIN 8 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [98] | ||
N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [41] | ||
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [99] | ||
N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [51] | ||
N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [100] | ||
N-phenyl-1H-pyrazole-3-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-phenyl-1H-pyrazole-3-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N-phenyl-1H-pyrazole-3-carboxamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [51] | ||
NSC-625987 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for NSC-625987. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NSC-625987 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [101] | ||
NU-6027 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for NU-6027. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NU-6027 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [98] | ||
NU-6102 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for NU-6102. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NU-6102 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [102] | ||
NU6140 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for NU6140. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NU6140 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [103] | ||
Oxindole 95 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Oxindole 95. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Oxindole 95 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [73] | ||
PF-228 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PF-228. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PF-228 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [104] | ||
PHA-690509 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PHA-690509. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PHA-690509 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [105] | ||
PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [51] | ||
Purvalanol A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Purvalanol A. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Purvalanol A through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [106] | ||
PYRAZOLOPYRIDAZINE 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PYRAZOLOPYRIDAZINE 1. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PYRAZOLOPYRIDAZINE 1 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [107] | ||
PYRAZOLOPYRIDAZINE 2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [108] | ||
RESCOVITINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for RESCOVITINE. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RESCOVITINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [85] | ||
SCH-546909 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for SCH-546909. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SCH-546909 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [109] | ||
SU9516 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for SU9516. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SU9516 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [107] | ||
TRIAZOLOPYRIMIDINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for TRIAZOLOPYRIMIDINE. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TRIAZOLOPYRIMIDINE through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [51] | ||
VER-54505 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for VER-54505. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of VER-54505 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [105] | ||
BAY 10-00394 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for BAY 10-00394. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BAY 10-00394 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [110] | ||
Olomoucine [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for Olomoucine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Olomoucine through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [111] | ||
PD-0183812 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for PD-0183812. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PD-0183812 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [112] | ||
R547 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for R547. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of R547 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [76] | ||
SCH 727965 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for SCH 727965. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SCH 727965 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [113] | ||
ZK 304709 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for ZK 304709. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ZK 304709 through regulating the expression of Cyclin-dependent kinase 2 (CDK2). | [1], [76] | ||
Cyclin-dependent kinase 4 (CDK4)
Apremilast [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Apremilast. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Apremilast through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [45] | ||
LY2835219 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for LY2835219. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LY2835219 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [114] | ||
Palbociclib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Palbociclib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Palbociclib through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [115] | ||
Ribociclib Succinate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Ribociclib Succinate. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Ribociclib Succinate through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [116] | ||
Trilaciclib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Trilaciclib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Trilaciclib through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [117] | ||
LEE011 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for LEE011. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LEE011 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [118] | ||
FCN-437 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for FCN-437. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of FCN-437 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [119] | ||
G1T38 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for G1T38. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of G1T38 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [120] | ||
GLR2007 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for GLR2007. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of GLR2007 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [76] | ||
P-276 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for P-276. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of P-276 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [21] | ||
P276-00 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for P276-00. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of P276-00 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [75] | ||
Ro 31-7453 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Ro 31-7453. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Ro 31-7453 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [121] | ||
AG-024322 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for AG-024322. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AG-024322 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [121] | ||
FN-1501 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for FN-1501. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of FN-1501 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [122] | ||
G1T28-1 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for G1T28-1. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of G1T28-1 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [121] | ||
P1446A-05 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for P1446A-05. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of P1446A-05 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [45] | ||
PF-07220060 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PF-07220060. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PF-07220060 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [82] | ||
PHA-793887 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PHA-793887. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PHA-793887 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [123] | ||
RGB-286638 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for RGB-286638. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RGB-286638 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [76] | ||
INOC-005 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for INOC-005. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of INOC-005 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [76] | ||
1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [124] | ||
1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [124] | ||
1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [84] | ||
1-Pyridin-2-yl-3-quinolin-5-yl-urea [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 1-Pyridin-2-yl-3-quinolin-5-yl-urea. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 1-Pyridin-2-yl-3-quinolin-5-yl-urea through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [124] | ||
10-hydroxy-18-methoxybetaenone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 10-hydroxy-18-methoxybetaenone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 10-hydroxy-18-methoxybetaenone through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [121] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [84] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [125] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [86] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [84] | ||
Cdk4 inhibitor III [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Cdk4 inhibitor III. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Cdk4 inhibitor III through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [73] | ||
Fascaplysin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Fascaplysin. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Fascaplysin through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [107] | ||
K00024 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for K00024. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of K00024 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [97] | ||
N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [126] | ||
NSC-625987 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for NSC-625987. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NSC-625987 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [101] | ||
NU-6102 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for NU-6102. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NU-6102 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [102] | ||
NU6140 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for NU6140. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NU6140 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [103] | ||
PYRAZOLOPYRIDAZINE 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PYRAZOLOPYRIDAZINE 1. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PYRAZOLOPYRIDAZINE 1 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [107] | ||
PYRAZOLOPYRIDAZINE 2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [124] | ||
Ro-0505124 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Ro-0505124. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Ro-0505124 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [127] | ||
BAY 10-00394 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for BAY 10-00394. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BAY 10-00394 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [128] | ||
CYC-103 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for CYC-103. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CYC-103 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [73] | ||
PD-0183812 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PD-0183812. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PD-0183812 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [121] | ||
R547 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for R547. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of R547 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [76] | ||
ZK 304709 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for ZK 304709. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ZK 304709 through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [76] | ||
Cysteines of Keap1 (KEAP1 Cysteines)
CXA10 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cysteines of Keap1 (KEAP1 Cysteines) is a therapeutic target for CXA10. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CXA10 through regulating the expression of Cysteines of Keap1 (KEAP1 Cysteines). | [1], [129] | ||
VCB101 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cysteines of Keap1 (KEAP1 Cysteines) is a therapeutic target for VCB101. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of VCB101 through regulating the expression of Cysteines of Keap1 (KEAP1 Cysteines). | [1], [130] | ||
VCB102 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Cysteines of Keap1 (KEAP1 Cysteines) is a therapeutic target for VCB102. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of VCB102 through regulating the expression of Cysteines of Keap1 (KEAP1 Cysteines). | [1], [131] | ||
E2F transcription factor 1 (E2F1)
ARQ-171 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | E2F transcription factor 1 (E2F1) is a therapeutic target for ARQ-171. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ARQ-171 through regulating the expression of E2F transcription factor 1 (E2F1). | [132], [133] | ||
ISIS 113019 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113019. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ISIS 113019 through regulating the expression of E2F transcription factor 1 (E2F1). | [132], [134] | ||
ISIS 113020 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113020. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ISIS 113020 through regulating the expression of E2F transcription factor 1 (E2F1). | [132], [134] | ||
ISIS 113021 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113021. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ISIS 113021 through regulating the expression of E2F transcription factor 1 (E2F1). | [132], [134] | ||
ISIS 113022 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113022. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ISIS 113022 through regulating the expression of E2F transcription factor 1 (E2F1). | [132], [134] | ||
ISIS 113048 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113048. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ISIS 113048 through regulating the expression of E2F transcription factor 1 (E2F1). | [132], [135] | ||
Ephrin type-B receptor 2 (EPHB2)
BVD-523 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for BVD-523. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BVD-523 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [136], [137] | ||
SEphB4-HSA [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for SEphB4-HSA. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SEphB4-HSA through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [136], [138] | ||
KO-947 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for KO-947. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of KO-947 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [21], [136] | ||
MK-8353 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for MK-8353. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MK-8353 through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [21], [136] | ||
AMP-PNP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for AMP-PNP. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [136], [139] | ||
SNEWIQPRLPQH [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-B receptor 2 (EPHB2) is a therapeutic target for SNEWIQPRLPQH. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SNEWIQPRLPQH through regulating the expression of Ephrin type-B receptor 2 (EPHB2). | [21], [136] | ||
Epidermal growth factor receptor (EGFR)
Afatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Afatinib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Afatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [75], [140] | ||
Cetuximab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cetuximab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Cetuximab through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [141] | ||
Dacomitinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Dacomitinib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Dacomitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [142] | ||
Epidermal growth factor [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Epidermal growth factor. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Epidermal growth factor through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [143] | ||
HEGF [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HEGF. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HEGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [144] | ||
Icotinib hydrochloride [Registered]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Icotinib hydrochloride. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Icotinib hydrochloride through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [145] | ||
Lapatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Lapatinib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Lapatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [146] | ||
Merimepodib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Merimepodib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Merimepodib through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [147] | ||
Necitumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Necitumumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Necitumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [148] | ||
NERATINIB MALEATE [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for NERATINIB MALEATE. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NERATINIB MALEATE through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [149] | ||
Nitroglycerin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Nitroglycerin. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Nitroglycerin through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [147] | ||
Panitumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Panitumumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Panitumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [150] | ||
SKI-758 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SKI-758. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SKI-758 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
Vandetanib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Vandetanib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Vandetanib through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [152] | ||
AC0010 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AC0010. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AC0010 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [153] | ||
Almonertinib [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Almonertinib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Almonertinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [154] | ||
Amivantamab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Amivantamab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Amivantamab through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [155] | ||
ASP1929 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ASP1929. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ASP1929 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [156] | ||
CO-1686 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CO-1686. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CO-1686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
DE-766 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for DE-766. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of DE-766 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [157] | ||
EGF816 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGF816. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EGF816 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
HKI-272 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HKI-272. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HKI-272 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [158] | ||
Indium-111 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Indium-111. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Indium-111 through regulating the expression of Epidermal growth factor receptor (EGFR). | [45], [140] | ||
Rindopepimut [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Rindopepimut. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Rindopepimut through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [159] | ||
SYM-004 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYM-004. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SYM-004 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [160] | ||
Varlitinib [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Varlitinib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Varlitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [13], [140] | ||
Zalutumumab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Zalutumumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Zalutumumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [142] | ||
ABT-414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ABT-414. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABT-414 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [141] | ||
ABX-EGF [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ABX-EGF. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABX-EGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [161] | ||
AFM24 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AFM24. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AFM24 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [162] | ||
ASP8273 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ASP8273. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ASP8273 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [163] | ||
BDTX-189 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BDTX-189. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BDTX-189 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [164] | ||
BMS-599626 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BMS-599626. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BMS-599626 through regulating the expression of Epidermal growth factor receptor (EGFR). | [75], [140] | ||
BMS-690514 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BMS-690514. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BMS-690514 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [159] | ||
CART-EGFR [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CART-EGFR. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CART-EGFR through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [165] | ||
CetuGEX [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CetuGEX. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CetuGEX through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [166] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CI-1033. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CI-1033 through regulating the expression of Epidermal growth factor receptor (EGFR). | [21], [140] | ||
CK-101 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CK-101. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CK-101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [21], [140] | ||
Depatuxizumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Depatuxizumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Depatuxizumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [21], [140] | ||
EGFR antisense DNA [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR antisense DNA. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EGFR antisense DNA through regulating the expression of Epidermal growth factor receptor (EGFR). | [21], [140] | ||
EGFR CART [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR CART. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EGFR CART through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [167] | ||
EMB-01 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EMB-01. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EMB-01 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [168] | ||
EMD 55900 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EMD 55900. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EMD 55900 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [169] | ||
HER1-VSSP vaccine [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HER1-VSSP vaccine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HER1-VSSP vaccine through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [170] | ||
HM-78136B [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HM-78136B. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HM-78136B through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [171] | ||
Matuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Matuzumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Matuzumab through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [172] | ||
MEHD-7945A [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MEHD-7945A. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MEHD-7945A through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [173] | ||
Pelitinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Pelitinib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Pelitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [174] | ||
RM-1929 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RM-1929. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RM-1929 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [175] | ||
SN-32793 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SN-32793. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SN-32793 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [176] | ||
Sym013 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Sym013. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Sym013 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [177] | ||
Sym015 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Sym015. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Sym015 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [167] | ||
Tarloxotinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Tarloxotinib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Tarloxotinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [178] | ||
TT-100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TT-100. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TT-100 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [179] | ||
VATALANIB [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for VATALANIB. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of VATALANIB through regulating the expression of Epidermal growth factor receptor (EGFR). | [45], [140] | ||
ZN-e4 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ZN-e4. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ZN-e4 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [180] | ||
AMG 595 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AMG 595. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AMG 595 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [181] | ||
Anti-EGFR CAR T [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR CAR T. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Anti-EGFR CAR T through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [182] | ||
AP32788 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AP32788. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AP32788 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [183] | ||
AST-1306 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AST-1306. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AST-1306 through regulating the expression of Epidermal growth factor receptor (EGFR). | [45], [140] | ||
BCA101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BCA101. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BCA101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [184] | ||
BIBX-1382 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BIBX-1382. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BIBX-1382 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [185] | ||
Cipatinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cipatinib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Cipatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [186] | ||
CLN-081 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CLN-081. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CLN-081 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [187] | ||
CUDC-101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CUDC-101. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CUDC-101 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [188] | ||
D2C7 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for D2C7. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of D2C7 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [189] | ||
EGFR806-specific CAR T cell [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR806-specific CAR T cell. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EGFR806-specific CAR T cell through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [190] | ||
IMGN289 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for IMGN289. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of IMGN289 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
JNJ-26483327 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for JNJ-26483327. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of JNJ-26483327 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [191] | ||
LY3164530 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LY3164530. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LY3164530 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [192] | ||
MCLA-158 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MCLA-158. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MCLA-158 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [193] | ||
MM-151 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MM-151. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MM-151 through regulating the expression of Epidermal growth factor receptor (EGFR). | [21], [140] | ||
MR1-1 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MR1-1. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MR1-1 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [194] | ||
PF-05230907 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PF-05230907. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PF-05230907 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [167] | ||
Pyrotinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Pyrotinib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Pyrotinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [195] | ||
S-222611 [Phase 1b]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for S-222611. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of S-222611 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
SI-B001 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SI-B001. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SI-B001 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [196] | ||
SYN004 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYN004. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SYN004 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [167] | ||
111In-hEGF [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 111In-hEGF. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 111In-hEGF through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [197] | ||
(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [198] | ||
(3-Bromo-phenyl)-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (3-Bromo-phenyl)-quinazolin-4-yl-amine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of (3-Bromo-phenyl)-quinazolin-4-yl-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [199] | ||
(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [200] | ||
(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [198] | ||
10-hydroxy-18-methoxybetaenone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 10-hydroxy-18-methoxybetaenone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 10-hydroxy-18-methoxybetaenone through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [198] | ||
2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [201] | ||
2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [202] | ||
2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [198] | ||
2-cyano-3-(3,4-dihydroxyphenyl)acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [198] | ||
2-methoxy-4-(2-nitrovinyl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 2-methoxy-4-(2-nitrovinyl)phenol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-methoxy-4-(2-nitrovinyl)phenol through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [198] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [84], [140] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [203] | ||
3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [204] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [205] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [206] | ||
3-Pyridin-4-yl-quinoline-6,7-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 3-Pyridin-4-yl-quinoline-6,7-diol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-Pyridin-4-yl-quinoline-6,7-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [207] | ||
4-(2-nitroprop-1-enyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitroprop-1-enyl)benzene-1,2-diol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(2-nitroprop-1-enyl)benzene-1,2-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [198] | ||
4-(2-nitrovinyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitrovinyl)benzene-1,2-diol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(2-nitrovinyl)benzene-1,2-diol through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [208] | ||
4-(2-nitrovinyl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(2-nitrovinyl)phenol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(2-nitrovinyl)phenol through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [198] | ||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [209] | ||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [199] | ||
4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [198] | ||
4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [210] | ||
4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [211] | ||
4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [212] | ||
4557W [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 4557W. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4557W through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [213] | ||
5,6-Bis-p-tolylamino-isoindole-1,3-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 5,6-Bis-p-tolylamino-isoindole-1,3-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 5,6-Bis-p-tolylamino-isoindole-1,3-dione through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [214] | ||
5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [215] | ||
6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [212] | ||
6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [212] | ||
6,7-diethoxy-4-styrylquinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-diethoxy-4-styrylquinazoline. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6,7-diethoxy-4-styrylquinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [212] | ||
6,7-dimethoxy-4-(2-phenylethynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [212] | ||
6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [212] | ||
6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline through regulating the expression of Epidermal growth factor receptor (EGFR). | [90], [140] | ||
6,7-dimethoxy-N-m-tolylquinazolin-4-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6,7-dimethoxy-N-m-tolylquinazolin-4-amine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6,7-dimethoxy-N-m-tolylquinazolin-4-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [205] | ||
6-chloro-N-(3-chlorophenyl)quinazolin-4-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [205] | ||
AFM-21 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AFM-21. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AFM-21 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
AG 112 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG 112. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AG 112 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [216] | ||
AG 9 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG 9. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AG 9 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
AG-213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG-213. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AG-213 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [198] | ||
AG-538 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG-538. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AG-538 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [217] | ||
AG1478 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AG1478. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AG1478 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [218] | ||
AGT-2000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AGT-2000. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AGT-2000 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
AL-6802 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AL-6802. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AL-6802 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
Anti-EGFR humanized mabs [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR humanized mabs. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Anti-EGFR humanized mabs through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
Anti-EGFR mab [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Anti-EGFR mab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Anti-EGFR mab through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
ARX-AHD [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ARX-AHD. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ARX-AHD through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [209] | ||
Benzyl-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Benzyl-quinazolin-4-yl-amine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Benzyl-quinazolin-4-yl-amine through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [210] | ||
Bmab-200 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Bmab-200. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Bmab-200 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
BPIQ-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for BPIQ-I. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BPIQ-I through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [219] | ||
CL-387785 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CL-387785. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CL-387785 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [211] | ||
Cochliobolic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Cochliobolic acid. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Cochliobolic acid through regulating the expression of Epidermal growth factor receptor (EGFR). | [126], [140] | ||
EDP-13 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EDP-13. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EDP-13 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
EGFR inhibitor [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for EGFR inhibitor. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EGFR inhibitor through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [220] | ||
Epitinib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Epitinib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Epitinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
FHT-2107 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for FHT-2107. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of FHT-2107 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
GI-3000 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for GI-3000. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of GI-3000 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
HDS-029 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HDS-029. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HDS-029 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [221] | ||
HKI-9924129 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HKI-9924129. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HKI-9924129 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [222] | ||
HM-61713B [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HM-61713B. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HM-61713B through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
HTS-00213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-00213. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HTS-00213 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [205] | ||
HTS-02876 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-02876. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HTS-02876 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [223] | ||
HTS-05058 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for HTS-05058. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HTS-05058 through regulating the expression of Epidermal growth factor receptor (EGFR). | [84], [140] | ||
ICR 62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ICR 62. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ICR 62 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [224] | ||
IPS-01003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for IPS-01003. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of IPS-01003 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
LA22-radioimmunoconjugates [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LA22-radioimmunoconjugates. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LA22-radioimmunoconjugates through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
LAVENDUSTIN A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for LAVENDUSTIN A. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LAVENDUSTIN A through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [212] | ||
mabionHER2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for mabionHER2. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of mabionHER2 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
MDP-01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MDP-01. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MDP-01 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
MG-111 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MG-111. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MG-111 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [225] | ||
MT-062 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for MT-062. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MT-062 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [226] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [227] | ||
N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [228] | ||
N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [217] | ||
N-(4-(phenylamino)quinazolin-6-yl)acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-(phenylamino)quinazolin-6-yl)acrylamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N-(4-(phenylamino)quinazolin-6-yl)acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [224] | ||
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [201] | ||
N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [199] | ||
N4-(3-chlorophenyl)quinazoline-4,6-diamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N4-(3-chlorophenyl)quinazoline-4,6-diamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N4-(3-chlorophenyl)quinazoline-4,6-diamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [226] | ||
N4-(3-methylphenyl)-4,6-quinazolinediamine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for N4-(3-methylphenyl)-4,6-quinazolinediamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N4-(3-methylphenyl)-4,6-quinazolinediamine through regulating the expression of Epidermal growth factor receptor (EGFR). | [84], [140] | ||
NRC-2694 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for NRC-2694. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NRC-2694 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
ON-128 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for ON-128. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ON-128 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [199] | ||
OSI-75 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for OSI-75. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of OSI-75 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [229] | ||
PD-0166326 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-0166326. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PD-0166326 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [200] | ||
PD-0173956 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-0173956. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PD-0173956 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [200] | ||
PD-158780 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-158780. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PD-158780 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [199] | ||
PD-168393 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-168393. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PD-168393 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [228] | ||
PD182905 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD182905. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PD182905 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [176] | ||
PF 5208766 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PF 5208766. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PF 5208766 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [230] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PP121. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PP121 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [231] | ||
RG-50810 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RG-50810. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RG-50810 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [223] | ||
RM-6427 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RM-6427. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RM-6427 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
Ro-4396686 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Ro-4396686. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Ro-4396686 through regulating the expression of Epidermal growth factor receptor (EGFR). | [84], [140] | ||
RX-1792 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RX-1792. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RX-1792 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
SYM-011 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for SYM-011. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SYM-011 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
TGF alpha [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TGF alpha. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TGF alpha through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
Theliatinib [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Theliatinib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Theliatinib through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [232] | ||
WHI-P154 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for WHI-P154. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of WHI-P154 through regulating the expression of Epidermal growth factor receptor (EGFR). | [90], [140] | ||
WZ-3146 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for WZ-3146. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of WZ-3146 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [151] | ||
AZD-9935 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AZD-9935. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AZD-9935 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [233] | ||
AZD4769 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for AZD4769. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AZD4769 through regulating the expression of Epidermal growth factor receptor (EGFR). | [75], [140] | ||
CGP-52411 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CGP-52411. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CGP-52411 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [234] | ||
CGP-53353 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for CGP-53353. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CGP-53353 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [176] | ||
Heparin-EGF-like factor [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for Heparin-EGF-like factor. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Heparin-EGF-like factor through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [235] | ||
PD-153035 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PD-153035. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PD-153035 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [236] | ||
PKI166 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for PKI166. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PKI166 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [237] | ||
RG7160 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for RG7160. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RG7160 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [238] | ||
TAK165 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Epidermal growth factor receptor (EGFR) is a therapeutic target for TAK165. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TAK165 through regulating the expression of Epidermal growth factor receptor (EGFR). | [140], [239] | ||
Forkhead box protein M1 (FOXM1)
(D-Arg)(9)-p19(ARF) 26-44 peptide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Forkhead box protein M1 (FOXM1) is a therapeutic target for (D-Arg)(9)-p19(ARF) 26-44 peptide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of (D-Arg)(9)-p19(ARF) 26-44 peptide through regulating the expression of Forkhead box protein M1 (FOXM1). | [240], [241] | ||
Frizzled-7 receptor (FZD7)
OMP-18R5 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Frizzled-7 receptor (FZD7) is a therapeutic target for OMP-18R5. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of OMP-18R5 through regulating the expression of Frizzled-7 receptor (FZD7). | [242], [243] | ||
G1/S-specific cyclin-D1 (CCND1)
ABT-263 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for ABT-263. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABT-263 through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [1], [244] | ||
Briciclib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [1], [21] | ||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [1], [84] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [1], [84] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [1], [245] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [1], [84] | ||
7-hydroxycoumarin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 7-hydroxycoumarin. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 7-hydroxycoumarin through regulating the expression of G1/S-specific cyclin-D1 (CCND1). | [1], [102] | ||
Hexokinase-2 (HK2)
VDA-1102 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hexokinase-2 (HK2) is a therapeutic target for VDA-1102. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of VDA-1102 through regulating the expression of Hexokinase-2 (HK2). | [246], [247] | ||
Insulin-like growth factor-I (IGF1)
Xentuzumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor-I (IGF1) is a therapeutic target for Xentuzumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Xentuzumab through regulating the expression of Insulin-like growth factor-I (IGF1). | [248], [249] | ||
BI-836845 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor-I (IGF1) is a therapeutic target for BI-836845. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BI-836845 through regulating the expression of Insulin-like growth factor-I (IGF1). | [167], [248] | ||
MEDI-573 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor-I (IGF1) is a therapeutic target for MEDI-573. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MEDI-573 through regulating the expression of Insulin-like growth factor-I (IGF1). | [248], [250] | ||
Interleukin-1 beta (IL1B)
Canakinumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Canakinumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Canakinumab through regulating the expression of Interleukin-1 beta (IL1B). | [40], [251] | ||
Diacerein [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Diacerein. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Diacerein through regulating the expression of Interleukin-1 beta (IL1B). | [40], [252] | ||
Gallium nitrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Gallium nitrate. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Gallium nitrate through regulating the expression of Interleukin-1 beta (IL1B). | [40], [253] | ||
Glucosamine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Glucosamine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Glucosamine through regulating the expression of Interleukin-1 beta (IL1B). | [40], [254] | ||
Rilonacept [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Rilonacept. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Rilonacept through regulating the expression of Interleukin-1 beta (IL1B). | [40], [255] | ||
XOMA 052 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for XOMA 052. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of XOMA 052 through regulating the expression of Interleukin-1 beta (IL1B). | [40], [256] | ||
ABT-981 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for ABT-981. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABT-981 through regulating the expression of Interleukin-1 beta (IL1B). | [40], [257] | ||
AC-201 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for AC-201. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AC-201 through regulating the expression of Interleukin-1 beta (IL1B). | [40], [258] | ||
LY-2189102 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for LY-2189102. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LY-2189102 through regulating the expression of Interleukin-1 beta (IL1B). | [40], [259] | ||
CYT-013-IL1bQb [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for CYT-013-IL1bQb. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CYT-013-IL1bQb through regulating the expression of Interleukin-1 beta (IL1B). | [40], [260] | ||
TT-301 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for TT-301. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TT-301 through regulating the expression of Interleukin-1 beta (IL1B). | [40], [261] | ||
Celastrol [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Celastrol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Celastrol through regulating the expression of Interleukin-1 beta (IL1B). | [40], [262] | ||
DVD-Ig [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for DVD-Ig. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of DVD-Ig through regulating the expression of Interleukin-1 beta (IL1B). | [12], [40] | ||
CDP-484 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for CDP-484. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CDP-484 through regulating the expression of Interleukin-1 beta (IL1B). | [40], [263] | ||
MAP kinase signal-integrating kinase 2 (MKNK2)
EFT508 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | MAP kinase signal-integrating kinase 2 (MKNK2) is a therapeutic target for EFT508. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EFT508 through regulating the expression of MAP kinase signal-integrating kinase 2 (MKNK2). | [136], [264] | ||
Nuclear factor erythroid 2-related factor 2 (Nrf2)
ABT-RTA-408 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for ABT-RTA-408. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABT-RTA-408 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [1], [265] | ||
CXA10 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for CXA10. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CXA10 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [1], [129] | ||
Omaveloxolone [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for Omaveloxolone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Omaveloxolone through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [1], [266] | ||
OT-551 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for OT-551. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of OT-551 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [1], [267] | ||
OT551 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for OT551. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of OT551 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [1], [131] | ||
SFX-01 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for SFX-01. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SFX-01 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [1], [268] | ||
HPP971 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for HPP971. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HPP971 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [1], [269] | ||
CAT4001 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for CAT4001. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CAT4001 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [1], [270] | ||
M102 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for M102. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of M102 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [1], [271] | ||
TFM735 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Nuclear factor erythroid 2-related factor 2 (Nrf2) is a therapeutic target for TFM735. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TFM735 through regulating the expression of Nuclear factor erythroid 2-related factor 2 (Nrf2). | [1], [266] | ||
Poly [ADP-ribose] polymerase 1 (PARP1)
KU-0058948 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for KU-0058948. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of KU-0058948 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [114], [272] | ||
Nicotinamide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Nicotinamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Nicotinamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [273] | ||
Niraparib Tosylate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Niraparib Tosylate. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Niraparib Tosylate through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [51], [272] | ||
CC-486 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for CC-486. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CC-486 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [274] | ||
Nicaraven [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Nicaraven. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Nicaraven through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [275] | ||
AG140699 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for AG140699. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AG140699 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [276] | ||
AMXI 5001 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for AMXI 5001. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AMXI 5001 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [277] | ||
PMID27841036-Compound-37 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for PMID27841036-Compound-37. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PMID27841036-Compound-37 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [278] | ||
Stenoparib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Stenoparib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Stenoparib through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [279] | ||
NMS-03305293 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for NMS-03305293. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NMS-03305293 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [280] | ||
CPH-102 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for CPH-102. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CPH-102 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [281] | ||
PJ34 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for PJ34. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PJ34 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [282] | ||
(E)-N-(4-Phenylthiazol-2-yl) cinnamamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for (E)-N-(4-Phenylthiazol-2-yl) cinnamamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of (E)-N-(4-Phenylthiazol-2-yl) cinnamamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [283] | ||
1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [283] | ||
1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [284] | ||
2,3-dihydro-1H-benzo[de]isoquinolin-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2,3-dihydro-1H-benzo[de]isoquinolin-1-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2,3-dihydro-1H-benzo[de]isoquinolin-1-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [285] | ||
2,8-Dimethyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2,8-Dimethyl-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2,8-Dimethyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
2-(2-Chlorophenyl)-2H-indazole-7-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(2-Chlorophenyl)-2H-indazole-7-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(2-Chlorophenyl)-2H-indazole-7-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [287] | ||
2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [51], [272] | ||
2-(3-Chlorophenyl)-2H-indazole-7-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(3-Chlorophenyl)-2H-indazole-7-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(3-Chlorophenyl)-2H-indazole-7-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [287] | ||
2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [288] | ||
2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [289] | ||
2-(4-Chlorophenyl)-2H-indazole-7-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Chlorophenyl)-2H-indazole-7-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(4-Chlorophenyl)-2H-indazole-7-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [287] | ||
2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [51], [272] | ||
2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
2-(4-methoxyphenyl)quinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-(4-methoxyphenyl)quinoline-8-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(4-methoxyphenyl)quinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [285] | ||
2-Benzyl-2H-indazole-7-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-Benzyl-2H-indazole-7-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-Benzyl-2H-indazole-7-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
2-ethylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-ethylquinoline-8-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-ethylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [285] | ||
2-Methylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-Methylquinoline-8-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-Methylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [285] | ||
2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [287] | ||
2-phenyl-2H-indazole-7-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-phenyl-2H-indazole-7-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-phenyl-2H-indazole-7-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [290] | ||
2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [287] | ||
2-phenylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2-phenylquinoline-8-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-phenylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [285] | ||
2H-Isoquinolin-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 2H-Isoquinolin-1-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2H-Isoquinolin-1-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
3-(4-aminophenyl)quinoxaline-5-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-(4-aminophenyl)quinoxaline-5-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(4-aminophenyl)quinoxaline-5-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [283] | ||
3-(4-cyanophenyl)quinoxaline-5-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-(4-cyanophenyl)quinoxaline-5-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(4-cyanophenyl)quinoxaline-5-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [283] | ||
3-(4-methoxyphenyl)quinoxaline-5-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-(4-methoxyphenyl)quinoxaline-5-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(4-methoxyphenyl)quinoxaline-5-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [283] | ||
3-aminobenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-aminobenzamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-aminobenzamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [291] | ||
3-aminobenzo[c][1,5]naphthyridin-6(5H)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-aminobenzo[c][1,5]naphthyridin-6(5H)-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-aminobenzo[c][1,5]naphthyridin-6(5H)-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [283] | ||
3-Ethenylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Ethenylquinoline-8-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-Ethenylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [285] | ||
3-Ethylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Ethylquinoline-8-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-Ethylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [285] | ||
3-Ethynylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Ethynylquinoline-8-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-Ethynylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [285] | ||
3-Hydroxy-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Hydroxy-benzamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-Hydroxy-benzamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
3-Methoxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Methoxybenzamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-Methoxybenzamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [41], [272] | ||
3-Methylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Methylquinoline-8-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-Methylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [285] | ||
3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [292] | ||
3-Phenylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Phenylquinoline-8-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-Phenylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [283] | ||
3-Prop-1-ynylquinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 3-Prop-1-ynylquinoline-8-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-Prop-1-ynylquinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [285] | ||
4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [293] | ||
4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [292] | ||
4-amino-1,8-naphthalimide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 4-amino-1,8-naphthalimide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-amino-1,8-naphthalimide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [278] | ||
4-benzylphthalazin-1(2H)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 4-benzylphthalazin-1(2H)-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-benzylphthalazin-1(2H)-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [283] | ||
4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [284] | ||
5-amino-3,4-dihydroisoquinolin-1(2H)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 5-amino-3,4-dihydroisoquinolin-1(2H)-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 5-amino-3,4-dihydroisoquinolin-1(2H)-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [290] | ||
5-aminoisoquinolin-1(2H)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 5-aminoisoquinolin-1(2H)-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 5-aminoisoquinolin-1(2H)-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [285] | ||
5-Chloro-2-methyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 5-Chloro-2-methyl-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 5-Chloro-2-methyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [294] | ||
5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [284] | ||
8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [295] | ||
8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [295] | ||
8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
8-Hydroxy-2-phenyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Hydroxy-2-phenyl-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 8-Hydroxy-2-phenyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
8-Methoxy-2-methyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Methoxy-2-methyl-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 8-Methoxy-2-methyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
8-Methoxy-2-phenyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Methoxy-2-phenyl-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 8-Methoxy-2-phenyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
8-Methyl-2-phenyl-3H-quinazolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Methyl-2-phenyl-3H-quinazolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 8-Methyl-2-phenyl-3H-quinazolin-4-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [286] | ||
8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [295] | ||
9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [292] | ||
9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for 9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [295] | ||
A-620223 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for A-620223. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of A-620223 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [282] | ||
AG-014376 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for AG-014376. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AG-014376 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [283] | ||
ANG-2684 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for ANG-2684. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ANG-2684 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [282] | ||
ANG-2864 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for ANG-2864. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ANG-2864 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [289] | ||
Benzo[c][1,5]naphthyridin-6(5H)-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Benzo[c][1,5]naphthyridin-6(5H)-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Benzo[c][1,5]naphthyridin-6(5H)-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [287] | ||
BPI-704001 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for BPI-704001. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BPI-704001 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [282] | ||
BZ3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for BZ3. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BZ3 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [296] | ||
BZ5 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for BZ5. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BZ5 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [296] | ||
BZ6 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for BZ6. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BZ6 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [293] | ||
Carba-Nicotinamide-Adenine-Dinucleotide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Carba-Nicotinamide-Adenine-Dinucleotide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Carba-Nicotinamide-Adenine-Dinucleotide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [41], [272] | ||
CEP-6800 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for CEP-6800. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CEP-6800 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [284] | ||
DR2313 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for DR2313. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of DR2313 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [278] | ||
EB-47 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for EB-47. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EB-47 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [296] | ||
HYDAMTIQ [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for HYDAMTIQ. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HYDAMTIQ through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [282] | ||
INO-1002 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for INO-1002. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of INO-1002 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [282] | ||
KR-33889 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for KR-33889. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of KR-33889 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [282] | ||
KU-58684 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for KU-58684. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of KU-58684 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [295] | ||
ME0328 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for ME0328. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ME0328 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [41], [272] | ||
N-(4-Phenylthiazol-2-yl)isonicotinamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for N-(4-Phenylthiazol-2-yl)isonicotinamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N-(4-Phenylthiazol-2-yl)isonicotinamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [283] | ||
PD-128763 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for PD-128763. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PD-128763 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [282] | ||
Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [287] | ||
Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [284] | ||
Quinoline-8-carboxamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Quinoline-8-carboxamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Quinoline-8-carboxamide through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [285] | ||
S-070 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for S-070. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of S-070 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [282] | ||
S-111 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for S-111. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of S-111 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [282] | ||
Thieno-phenanthridin-6-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for Thieno-phenanthridin-6-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Thieno-phenanthridin-6-one through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [278] | ||
TI3 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for TI3. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TI3 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [296] | ||
TI4 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for TI4. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TI4 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [296] | ||
[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [296] | ||
NU1025 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Poly [ADP-ribose] polymerase 1 (PARP1) is a therapeutic target for NU1025. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NU1025 through regulating the expression of Poly [ADP-ribose] polymerase 1 (PARP1). | [272], [277] | ||
Programmed cell death 1 ligand 1 (PD-L1)
Atezolizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Atezolizumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Atezolizumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [297] | ||
Avelumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Avelumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Avelumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [114], [132] | ||
Bavencio [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Bavencio. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Bavencio through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [298] | ||
Durvalumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Durvalumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Durvalumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [299] | ||
RG-7446 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for RG-7446. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RG-7446 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [300] | ||
CS1001 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CS1001. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CS1001 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [301] | ||
KN046 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for KN046. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of KN046 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [302] | ||
MEDI4736 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for MEDI4736. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MEDI4736 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [303] | ||
MPDL-3280A [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for MPDL-3280A. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MPDL-3280A through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [304] | ||
BGB-A333 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for BGB-A333. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BGB-A333 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [305] | ||
Bintrafusp alfa [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Bintrafusp alfa. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Bintrafusp alfa through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [306] | ||
CX-072 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CX-072. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CX-072 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [307] | ||
GS-4224 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for GS-4224. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of GS-4224 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [308] | ||
INCB86550 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for INCB86550. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of INCB86550 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [309] | ||
KN035 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for KN035. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of KN035 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [310] | ||
M7824 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for M7824. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of M7824 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [167] | ||
NM21-1480 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for NM21-1480. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NM21-1480 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [299] | ||
Pidilizumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Pidilizumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Pidilizumab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [21], [132] | ||
ALPN-202 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for ALPN-202. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ALPN-202 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [311] | ||
Anti-PD-L1 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Anti-PD-L1. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Anti-PD-L1 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [312] | ||
Anti-PD-L1 CSR T cells [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Anti-PD-L1 CSR T cells. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Anti-PD-L1 CSR T cells through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [21], [132] | ||
BMS-986189 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for BMS-986189. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BMS-986189 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [299] | ||
CA-170 [Phase 1]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CA-170. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CA-170 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [167] | ||
| Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CA-170. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CA-170 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [313] | |||
Cosibelimab [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for Cosibelimab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Cosibelimab through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [314] | ||
FAZ053 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for FAZ053. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of FAZ053 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [299] | ||
FS118 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for FS118. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of FS118 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [315] | ||
GEN1046 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for GEN1046. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of GEN1046 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [316] | ||
IBI318 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for IBI318. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of IBI318 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [317] | ||
INBRX-105 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for INBRX-105. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of INBRX-105 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [318] | ||
KD033 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for KD033. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of KD033 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [319] | ||
LY3300054 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for LY3300054. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LY3300054 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [21], [132] | ||
LY3415244 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for LY3415244. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LY3415244 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [320] | ||
MCLA-145 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for MCLA-145. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MCLA-145 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [321] | ||
MSB2311 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for MSB2311. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MSB2311 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [299] | ||
PD-L1 t-haNK [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for PD-L1 t-haNK. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PD-L1 t-haNK through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [322] | ||
RG6084 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for RG6084. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RG6084 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [167] | ||
TAK-252 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for TAK-252. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TAK-252 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [323] | ||
CA-327 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Programmed cell death 1 ligand 1 (PD-L1) is a therapeutic target for CA-327. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CA-327 through regulating the expression of Programmed cell death 1 ligand 1 (PD-L1). | [132], [299] | ||
Protein phosphatase 1A (PPM1A)
VP-102 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Protein phosphatase 1A (PPM1A) is a therapeutic target for VP-102. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of VP-102 through regulating the expression of Protein phosphatase 1A (PPM1A). | [324], [325] | ||
Proto-oncogene c-Myc (MYC)
AVI-5126 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for AVI-5126. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AVI-5126 through regulating the expression of Proto-oncogene c-Myc (MYC). | [132], [326] | ||
Resten-NG [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). | [121], [132] | ||
TWS-119 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). | [132], [327] | ||
Pyruvate kinase M2 (PKM)
CAP-232 [Phase 2a]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Pyruvate kinase M2 (PKM) is a therapeutic target for CAP-232. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CAP-232 through regulating the expression of Pyruvate kinase M2 (PKM). | [328], [329] | ||
TP-1454 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Pyruvate kinase M2 (PKM) is a therapeutic target for TP-1454. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TP-1454 through regulating the expression of Pyruvate kinase M2 (PKM). | [45], [328] | ||
RAC-alpha serine/threonine-protein kinase (AKT1)
AZD5363 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for AZD5363. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AZD5363 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [21], [330] | ||
Enzastaurin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Enzastaurin. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Enzastaurin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [331] | ||
GDC-0068 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GDC-0068. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of GDC-0068 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [21], [330] | ||
ARQ 092 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 092. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ARQ 092 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [332] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1033. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CI-1033 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [21], [330] | ||
CMX-2043 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CMX-2043. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CMX-2043 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [75], [330] | ||
GSK2110183 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GSK2110183. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of GSK2110183 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [333] | ||
PTX-200 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for PTX-200. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PTX-200 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [21], [330] | ||
RX-0201 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RX-0201. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RX-0201 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [334] | ||
Triciribine prodrug [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Triciribine prodrug. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Triciribine prodrug through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [190], [330] | ||
ARQ 751 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 751. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ARQ 751 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [334] | ||
BMS-754807 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS-754807. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BMS-754807 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [335] | ||
M2698 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for M2698. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of M2698 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [21], [330] | ||
(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [336] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [102], [330] | ||
4,5,6-trihydroxy-3-methylphthalide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6-trihydroxy-3-methylphthalide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4,5,6-trihydroxy-3-methylphthalide through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [336] | ||
A-443654 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-443654. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of A-443654 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [336] | ||
A-674563 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-674563. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of A-674563 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [337] | ||
Akt inhibitor VIII [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Akt inhibitor VIII. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Akt inhibitor VIII through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [41], [330] | ||
ALM-301 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ALM-301. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ALM-301 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [338] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Bisindolylmaleimide-I. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [339] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [336] | ||
BX-517 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BX-517. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BX-517 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [340] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1040. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CI-1040 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [334] | ||
Inositol 1,3,4,5-Tetrakisphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Inositol 1,3,4,5-Tetrakisphosphate. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Inositol 1,3,4,5-Tetrakisphosphate through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [341] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for KN-62. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of KN-62 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [339] | ||
Lactoquinomycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Lactoquinomycin. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Lactoquinomycin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [342] | ||
LD-101 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for LD-101. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LD-101 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [334] | ||
MYRIOCIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for MYRIOCIN. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MYRIOCIN through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [343] | ||
NU-1001-41 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for NU-1001-41. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of NU-1001-41 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [334] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RO-316233. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RO-316233 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [336] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Ro31-8220. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Ro31-8220 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [344] | ||
SB-747651A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for SB-747651A. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SB-747651A through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [108], [330] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for STAUROSPORINONE. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of STAUROSPORINONE through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [343] | ||
VLI-27 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for VLI-27. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of VLI-27 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [330], [334] | ||
Squalestatin 1 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Squalestatin 1. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Squalestatin 1 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [21], [330] | ||
Serine/threonine-protein kinase mTOR (mTOR)
Glasdegib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Glasdegib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Glasdegib through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [345] | ||
Novolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Novolimus. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Novolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [42], [330] | ||
Temsirolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Temsirolimus. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Temsirolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [346] | ||
Zotarolimus [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Zotarolimus. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Zotarolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
Ridaforolimus [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Ridaforolimus. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Ridaforolimus through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [347] | ||
ABI-009 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for ABI-009. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABI-009 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [348] | ||
AZD-2014 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AZD-2014. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AZD-2014 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
BEZ235 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for BEZ235. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BEZ235 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [21], [330] | ||
BGT226 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for BGT226. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BGT226 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
CC-223 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for CC-223. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CC-223 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [349] | ||
INK128 [Phase 2]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for INK128. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of INK128 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [350] | ||
| Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for INK128. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of INK128 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [369] | |||
LY3023414 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for LY3023414. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LY3023414 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [351] | ||
ME-344 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for ME-344. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ME-344 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [352] | ||
MM-141 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for MM-141. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MM-141 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [21], [330] | ||
OSI-027 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for OSI-027. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of OSI-027 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [353] | ||
PF-04691502 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-04691502. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PF-04691502 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [354] | ||
PF-05212384 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-05212384. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PF-05212384 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [355] | ||
PQR309 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PQR309. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PQR309 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [356] | ||
Salirasib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Salirasib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Salirasib through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
SAR245409 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SAR245409. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SAR245409 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [357] | ||
SF1126 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SF1126. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SF1126 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [21], [330] | ||
BI 860585 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for BI 860585. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BI 860585 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [358] | ||
DS-3078 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for DS-3078. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of DS-3078 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [359] | ||
DS-7423 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for DS-7423. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of DS-7423 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [360] | ||
GDC-0349 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for GDC-0349. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of GDC-0349 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
LAM-001 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for LAM-001. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of LAM-001 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [361] | ||
PWT-33597 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PWT-33597. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PWT-33597 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [190], [330] | ||
VS-5584 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for VS-5584. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of VS-5584 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [362] | ||
(4-(6-morpholino-9H-purin-2-yl)phenyl)methanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [363] | ||
2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [364] | ||
2-(6-morpholino-9H-purin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-(6-morpholino-9H-purin-2-yl)phenol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-(6-morpholino-9H-purin-2-yl)phenol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [363] | ||
2-chloro-N-(6-cyanopyridin-3-yl)propanamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-chloro-N-(6-cyanopyridin-3-yl)propanamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-chloro-N-(6-cyanopyridin-3-yl)propanamide through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [365] | ||
2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [366] | ||
3-(6-morpholino-9H-purin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 3-(6-morpholino-9H-purin-2-yl)phenol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 3-(6-morpholino-9H-purin-2-yl)phenol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [363] | ||
4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [363] | ||
4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [367] | ||
4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [363] | ||
4-(6-morpholino-9H-purin-2-yl)phenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for 4-(6-morpholino-9H-purin-2-yl)phenol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 4-(6-morpholino-9H-purin-2-yl)phenol through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [363] | ||
AP-21967 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AP-21967. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AP-21967 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [364] | ||
AR-mTOR-26 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AR-mTOR-26. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AR-mTOR-26 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
C-16-(S)-3-methylindolerapamycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for C-16-(S)-3-methylindolerapamycin. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of C-16-(S)-3-methylindolerapamycin through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [363] | ||
CU-906 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for CU-906. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CU-906 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
EC-0565 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for EC-0565. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EC-0565 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
EC-0845 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for EC-0845. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EC-0845 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
EM-101 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for EM-101. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of EM-101 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [368] | ||
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [366] | ||
HM-5016699 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for HM-5016699. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of HM-5016699 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
OXA-01 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for OXA-01. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of OXA-01 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
P-2281 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for P-2281. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of P-2281 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
P-6915 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for P-6915. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of P-6915 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
PF-03772304 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-03772304. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PF-03772304 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
PF-05094037 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PF-05094037. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PF-05094037 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [370] | ||
PP-242 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PP-242. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PP-242 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [214], [330] | ||
PP121 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PP121. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PP121 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [221], [330] | ||
Rapamycin complexed with immunophilin FKBP12 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Rapamycin complexed with immunophilin FKBP12. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Rapamycin complexed with immunophilin FKBP12 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [366] | ||
SB-2280 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SB-2280. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SB-2280 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
SX-MTR1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SX-MTR1. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SX-MTR1 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
torin 1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for torin 1. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of torin 1 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [221], [330] | ||
Torin2 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for Torin2. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Torin2 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [371] | ||
X-387 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for X-387. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of X-387 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [138], [330] | ||
AZD8055 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for AZD8055. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AZD8055 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [372] | ||
SCR-44001 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for SCR-44001. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of SCR-44001 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [373] | ||
TAFA-93 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for TAFA-93. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TAFA-93 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). | [330], [374] | ||
Transferrin receptor protein 1 (TFRC)
ABBV-CX-2029 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Transferrin receptor protein 1 (TFRC) is a therapeutic target for ABBV-CX-2029. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABBV-CX-2029 through regulating the expression of Transferrin receptor protein 1 (TFRC). | [375], [376] | ||
Tumor necrosis factor (TNF)
Adalimumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Adalimumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Adalimumab through regulating the expression of Tumor necrosis factor (TNF). | [7], [377] | ||
Certolizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Certolizumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Certolizumab through regulating the expression of Tumor necrosis factor (TNF). | [7], [378] | ||
Enbrel [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Enbrel. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Enbrel through regulating the expression of Tumor necrosis factor (TNF). | [7], [379] | ||
Etanercept [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Etanercept. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Etanercept through regulating the expression of Tumor necrosis factor (TNF). | [7], [380] | ||
Golimumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Golimumab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Golimumab through regulating the expression of Tumor necrosis factor (TNF). | [7], [381] | ||
Infliximab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Infliximab. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Infliximab through regulating the expression of Tumor necrosis factor (TNF). | [7], [382] | ||
Lenalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Lenalidomide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Lenalidomide through regulating the expression of Tumor necrosis factor (TNF). | [7], [254] | ||
Nafamostat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Nafamostat. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Nafamostat through regulating the expression of Tumor necrosis factor (TNF). | [7], [383] | ||
Pentoxifylline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Pentoxifylline. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Pentoxifylline through regulating the expression of Tumor necrosis factor (TNF). | [7], [384] | ||
Thalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Thalidomide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Thalidomide through regulating the expression of Tumor necrosis factor (TNF). | [7], [374] | ||
ABP 501 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABP 501. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABP 501 through regulating the expression of Tumor necrosis factor (TNF). | [7], [385] | ||
CPL-7075 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CPL-7075. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CPL-7075 through regulating the expression of Tumor necrosis factor (TNF). | [7], [386] | ||
Golnerminogene pradenovac [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Golnerminogene pradenovac. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Golnerminogene pradenovac through regulating the expression of Tumor necrosis factor (TNF). | [7], [387] | ||
PF-06410293 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-06410293. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PF-06410293 through regulating the expression of Tumor necrosis factor (TNF). | [7], [388] | ||
PF-06438179 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-06438179. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PF-06438179 through regulating the expression of Tumor necrosis factor (TNF). | [7], [389] | ||
ABT-122 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABT-122. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABT-122 through regulating the expression of Tumor necrosis factor (TNF). | [7], [390] | ||
AN0128 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AN0128. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AN0128 through regulating the expression of Tumor necrosis factor (TNF). | [7], [391] | ||
AP-301-IH [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AP-301-IH. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AP-301-IH through regulating the expression of Tumor necrosis factor (TNF). | [7], [392] | ||
ART621 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ART621. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ART621 through regulating the expression of Tumor necrosis factor (TNF). | [7], [188] | ||
BAICALEIN [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for BAICALEIN. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BAICALEIN through regulating the expression of Tumor necrosis factor (TNF). | [7], [393] | ||
COVA322 [Phase 1/2a]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for COVA322. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of COVA322 through regulating the expression of Tumor necrosis factor (TNF). | [7], [394] | ||
DLX-105 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for DLX-105. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of DLX-105 through regulating the expression of Tumor necrosis factor (TNF). | [7], [395] | ||
ESBA-105 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ESBA-105. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ESBA-105 through regulating the expression of Tumor necrosis factor (TNF). | [7], [396] | ||
Ortataxel [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Ortataxel. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Ortataxel through regulating the expression of Tumor necrosis factor (TNF). | [7], [397] | ||
Pegsunercept [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Pegsunercept. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Pegsunercept through regulating the expression of Tumor necrosis factor (TNF). | [7], [398] | ||
RDP58 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for RDP58. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of RDP58 through regulating the expression of Tumor necrosis factor (TNF). | [7], [399] | ||
TNF alpha kinoid [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for TNF alpha kinoid. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TNF alpha kinoid through regulating the expression of Tumor necrosis factor (TNF). | [7], [400] | ||
ABBV-257 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABBV-257. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABBV-257 through regulating the expression of Tumor necrosis factor (TNF). | [7], [401] | ||
AST-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AST-005. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AST-005 through regulating the expression of Tumor necrosis factor (TNF). | [7], [39] | ||
AVX-470 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AVX-470. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AVX-470 through regulating the expression of Tumor necrosis factor (TNF). | [7], [39] | ||
CYT-609 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CYT-609. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CYT-609 through regulating the expression of Tumor necrosis factor (TNF). | [7], [402] | ||
INB03 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for INB03. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of INB03 through regulating the expression of Tumor necrosis factor (TNF). | [7], [403] | ||
PF-05230905 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-05230905. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PF-05230905 through regulating the expression of Tumor necrosis factor (TNF). | [7], [267] | ||
PMI-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PMI-005. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PMI-005 through regulating the expression of Tumor necrosis factor (TNF). | [7], [404] | ||
ABX-0401 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABX-0401. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ABX-0401 through regulating the expression of Tumor necrosis factor (TNF). | [7], [12] | ||
Celastrol [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Celastrol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Celastrol through regulating the expression of Tumor necrosis factor (TNF). | [7], [45] | ||
2-Propanol, Isopropanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for 2-Propanol, Isopropanol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of 2-Propanol, Isopropanol through regulating the expression of Tumor necrosis factor (TNF). | [7], [405] | ||
DOM-0215 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for DOM-0215. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of DOM-0215 through regulating the expression of Tumor necrosis factor (TNF). | [7], [406] | ||
IK-862 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for IK-862. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of IK-862 through regulating the expression of Tumor necrosis factor (TNF). | [7], [407] | ||
PKF-241-466 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PKF-241-466. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PKF-241-466 through regulating the expression of Tumor necrosis factor (TNF). | [7], [407] | ||
PKF-242-484 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PKF-242-484. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PKF-242-484 through regulating the expression of Tumor necrosis factor (TNF). | [7], [408] | ||
Y-39041 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Y-39041. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Y-39041 through regulating the expression of Tumor necrosis factor (TNF). | [7], [409] | ||
ALS-00T2-0501 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ALS-00T2-0501. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ALS-00T2-0501 through regulating the expression of Tumor necrosis factor (TNF). | [7], [410] | ||
AME-527 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AME-527. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of AME-527 through regulating the expression of Tumor necrosis factor (TNF). | [7], [406] | ||
Camobucol [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Camobucol. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Camobucol through regulating the expression of Tumor necrosis factor (TNF). | [7], [411] | ||
CDP571 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CDP571. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CDP571 through regulating the expression of Tumor necrosis factor (TNF). | [7], [412] | ||
CRx-191 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CRx-191. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CRx-191 through regulating the expression of Tumor necrosis factor (TNF). | [7], [413] | ||
CYT-007-TNFQb [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CYT-007-TNFQb. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CYT-007-TNFQb through regulating the expression of Tumor necrosis factor (TNF). | [7], [414] | ||
FR-133605 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for FR-133605. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of FR-133605 through regulating the expression of Tumor necrosis factor (TNF). | [7], [415] | ||
ISIS 104838 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ISIS 104838. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ISIS 104838 through regulating the expression of Tumor necrosis factor (TNF). | [7], [416] | ||
MDL-201112 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for MDL-201112. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of MDL-201112 through regulating the expression of Tumor necrosis factor (TNF). | [7], [417] | ||
PNU-282987 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PNU-282987. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PNU-282987 through regulating the expression of Tumor necrosis factor (TNF). | [7], [32] | ||
Segard [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Segard. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Segard through regulating the expression of Tumor necrosis factor (TNF). | [7], [418] | ||
TNFQb therapeutic vaccines [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for TNFQb therapeutic vaccines. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of TNFQb therapeutic vaccines through regulating the expression of Tumor necrosis factor (TNF). | [7], [419] | ||
Ubiquitin carboxyl-terminal hydrolase 14 (USP14)
BAP-15 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin carboxyl-terminal hydrolase 14 (USP14) is a therapeutic target for BAP-15. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of BAP-15 through regulating the expression of Ubiquitin carboxyl-terminal hydrolase 14 (USP14). | [420], [421] | ||
IU1 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ubiquitin carboxyl-terminal hydrolase 14 (USP14) is a therapeutic target for IU1. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of IU1 through regulating the expression of Ubiquitin carboxyl-terminal hydrolase 14 (USP14). | [420], [422] | ||
References